Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript

XENOPORT INC (XNPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/01/2011 BW XenoPort Announces New Employment Inducement Award
05/04/2011 BW XenoPort Reports First Quarter Financial Results
04/27/2011 BW XenoPort to Release First Quarter Financial Results on May 4, 2011
04/25/2011 BW XenoPort Announces FDA Agreement on a Special Protocol Assessment for a Pivotal Phase 3 Clinical Trial of Arbaclofen Placarbil for Spasticity in MS Patients
04/18/2011 MW XenoPort and Zalicus Poised for Growth as Earnings Trends Improve
04/13/2011 BW XenoPort Announces Presentation of Preclinical Data for Novel Fumarate Analog XP23829 at the 63rd Annual Meeting of the American Academy of Neurology
03/21/2011 BW XenoPort Reports Results from a Phase 2b Clinical Trial of Arbaclofen Placarbil as Adjunctive Treatment for Patients with GERD
02/23/2011 BW XenoPort to Present at Upcoming Healthcare Conferences
02/16/2011 BW XenoPort Reports Fourth Quarter and Year-End 2010 Financial Results
12/09/2010 BW XenoPort Announces Pricing of Public Offering of Common Stock
11/23/2010 BW XenoPort Awarded Grant from The Michael J. Fox Foundation
11/08/2010 BW XenoPort Reports Third Quarter Financial Results
11/05/2010 BW XenoPort Announces New Employment Inducement Award
11/05/2010 BW XenoPort to Present at Upcoming Healthcare Conferences
11/01/2010 BW XenoPort to Release Third Quarter Financial Results on November 8, 2010
10/13/2010 BW XenoPort Announces Presentation of Preclinical Data for Novel Fumarate Analog XP23829 at ECTRIMS
10/01/2010 BW XenoPort Announces New Employment Inducement Awards
09/28/2010 BW XenoPort Announces Presentation of New Data for XP21279 at World Parkinson Congress
09/24/2010 BW Harwood Feffer LLP Files Class Action On Behalf Of Purchasers Of XenoPort, Inc. Securities For The Enlarged Class Period March 16, 2009 Through February 17, 2010
09/13/2010 BW XenoPort Announces Plans for Phase 3 Development of Arbaclofen Placarbil for Spasticity
09/10/2010 BW Kahn Swick & Foti, LLC and Former Louisiana Attorney General Notify XenoPort Shareholders With Large Financial Interests of Securities Fraud Class Action - XNPT
09/03/2010 BW CORRECTING and REPLACING XenoPort Announces New Employment Inducement Award
08/26/2010 BW XenoPort Announces Changes to Executive Team
08/12/2010 MW Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 From Investment in XenoPort, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the September 27, 2010 Lead Plaintiff Deadline
07/30/2010 MW Dyer & Berens LLP Files Class Action Lawsuit on Behalf of Investors Who Purchased the Common Stock of XenoPort, Inc. -- XNPT
07/30/2010 MW Kahn Swick & Foti, LLC and Former Louisiana Attorney General Notify XenoPort Shareholders of Class Action Securities Fraud on Behalf of XNPT Shareholders From May 5, 2009 to February 17, 2010 - XNPT
07/30/2010 BW Kendall Law Group Begins Investigation on Behalf of XenoPort, Inc. Shareholders
07/29/2010 BW Bernstein Liebhard LLP Announces Filing of Action on Behalf of Investors in XenoPort, Inc.
07/28/2010 MW Izard Nobel LLP Announces Class Action Lawsuit Against XenoPort, Inc.
07/27/2010 BW XenoPort to Release Second Quarter Financial Results on August 5, 2010
07/26/2010 BW XenoPort to Present at the Wedbush Life Sciences Conference
07/23/2010 BW XenoPort Announces Presentation of Preclinical Data for Acamprosate Prodrug at Fragile X Syndrome Conference
07/02/2010 BW XenoPort Announces New Employment Inducement Awards
05/18/2010 BW XenoPort to Present at the 2010 Citi Health Care Conference
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy